Trial reportBMC medical research methodology2006
Estimation of dynamical model parameters taking into account undetectable marker values.
Trial report in BMC medical research methodology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00221650 (Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.Antimicrobial agents and chemotherapy · 2014Trial
- Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.Proceedings of the National Academy of Sciences of the United States of America · 2011Trial
- BCG vaccination reduces the rate of Mycobacterium tuberculosis dissemination between murine lungs.Research square · 2026Article
- BCG vaccination reduces the rate of Mycobacterium tuberculosis dissemination between murine lungs.bioRxiv : the preprint server for biology · 2026Article
- Compare the marginal effects for environmental exposure and biomonitoring data with repeated measurements and values below the limit of detection.Journal of exposure science & environmental epidemiology · 2024Article
- Modeling the CD8+ T cell immune response to influenza infection in adult and aged mice.Journal of theoretical biology · 2024Article
- Confidence interval comparison: Precision of maximum likelihood estimates in LLOQ affected data.PloS one · 2023Article
- Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin.PLoS computational biology · 2021Article
- In-host Mathematical Modelling of COVID-19 in Humans.Annual reviews in control · 2020Article
- CD8+ lymphocyte control of SIV infection during antiretroviral therapy.PLoS pathogens · 2018Article
- Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.Pharmaceutical research · 2017Article
- Analysis of Censored Longitudinal Data with Skewness and a Terminal Event.Communications in statistics: Simulation and computation · 2017Article
- Article
- Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).AIDS (London, England) · 2015Article
- Effects of aging on influenza virus infection dynamics.Journal of virology · 2014Article
- Bayesian semiparametric mixture Tobit models with left censoring, skewness, and covariate measurement errors.Statistics in medicine · 2013Article
- Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.CPT: pharmacometrics & systems pharmacology · 2013Article
- Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.BMC medical research methodology · 2013Article
- Bayesian inference for a nonlinear mixed-effects Tobit model with multivariate skew-t distributions: application to AIDS studies.The international journal of biostatistics · 2012Article
- Modeling within-host dynamics of influenza virus infection including immune responses.PLoS computational biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMathematical models are widely used for studying the dynamic of infectious agents such as hepatitis C virus (HCV). Most often, model parameters are estimated using standard least-square procedures for each individual. Hierarchical models have been proposed in such applications. However, another issue is the left-censoring (undetectable values) of plasma viral load due to the lack of sensitivity of assays used for quantification. A method is proposed to take into account left-censored values for estimating parameters of non linear mixed models and its impact is demonstrated through a simulation study and an actual clinical trial of anti-HCV drugs.
methodsThe method consists in a full likelihood approach distinguishing the contribution of observed and left-censored measurements assuming a lognormal distribution of the outcome. Parameters of analytical solution of system of differential equations taking into account left-censoring are estimated using standard software.
resultsA simulation study with only 14% of measurements being left-censored showed that model parameters were largely biased (from -55% to +133% according to the parameter) with the exception of the estimate of initial outcome value when left-censored viral load values are replaced by the value of the threshold. When left-censoring was taken into account, the relative bias on fixed effects was equal or less than 2%. Then, parameters were estimated using the 100 measurements of HCV RNA available (with 12% of left-censored values) during the first 4 weeks following treatment initiation in the 17 patients included in the trial. Differences between estimates according to the method used were clinically significant, particularly on the death rate of infected cells. With the crude approach the estimate was 0.13 day-1 (95% confidence interval [CI]: 0.11; 0.17) compared to 0.19 day-1 (CI: 0.14; 0.26) when taking into account left-censoring. The relative differences between estimates of individual treatment efficacy according to the method used varied from 0.001% to 37%.
conclusionWe proposed a method that gives unbiased estimates if the assumed distribution is correct (e.g. lognormal) and that is easy to use with standard software.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.